Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436370 | 0.95 | DRD4 (0.59) | DRD4OPRL1KCNH2OPRM1MCHR1 | |
| SCHEMBL3436631 | 0.91 | PROKR1 (0.47) | DRD4OPRL1HSP90AA1HSP90AB1HSD11B1 | |
| SCHEMBL3436380 | 0.88 | DRD4 (0.52) | DRD4OPRL1KCNH2HSP90AA1HSP90AB1 | |
| SCHEMBL3436055 | 0.85 | DRD4 (0.41) | DRD4OPRL1 | |
| SCHEMBL3436049 | 0.79 | CYP2C19 (0.44) | DRD4KDM4E | |
| Hydrochloric Acid SCHEMBL2078695 | 0.78 | CYP2C19 (0.43) | DRD4KDM4E | |
| SCHEMBL520958 | 0.77 | DRD4 (0.47) | DRD4 | |
| SCHEMBL4185437 | 0.77 | DRD2 (0.63) | DRD4 | |
| SCHEMBL3436627 | 0.76 | DRD4 (0.48) | DRD4OPRL1KCNH2OPRM1 | |
| SCHEMBL3436615 | 0.76 | OPRL1 (0.50) | DRD4OPRL1KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | DRD4 4535/4885OPRL1 51/4885KCNH2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.